The role of adhesion molecules in renal cell cancers Böbrek hücreli̇kanserlerde adezyon molekülleri̇ni̇n yeṙi


POLAT F., Sözen S., Acar C., BUKAN N., Coşkun U., Bozkirli I.

Turk Uroloji Dergisi, cilt.32, sa.4, ss.458-461, 2006 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 4
  • Basım Tarihi: 2006
  • Dergi Adı: Turk Uroloji Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.458-461
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction: In this study we aimed to investigate the relationship between adhesion molecules and pathologic stage, Fuhrman nuclear grade of tumors in renal cell cancers. Materials and Methods: 26 patients who underwent radical nephrectomy for renal cell carcinoma between 2001-2003 in Gazi University School of Medicine, Department of Urology and 8 healthy individuals were enrolled into the study. Patients were classified into four groups according to TNM staging system and Fuhrman nuclear grading as T1N0M0, T2-4N0M0, Grade 1, 2 and Grade 3, 4. Levels of ICAM-1, VCAM-1 and P-Selectin were measured in blood sample of the patients following 12 hours starvation before radical nephrectomy and compared with results of control group. Results: ICAM-1, VCAM-1 and P-Selectin levels of Grade 3, 4 patients were significantly higher than control group, whereas there was no difference between Grade 1, 2 and Grade 3, 4 patients. When the patients were investigated according to pathological stage, all the three parameters were higher than control group in T2-4N0M0 patients, whereas this difference did not reach statistically significant level in VCAM-1 parameter. Conclusion: The unpredictable clinical behavior of renal cell carcinomas is the subject of researches as such in past. In our study, the presence of increased cell adhesion molecules in blood samples of high stage and grade renal cell carcinomas suggest that adjuvant systemic therapy may be required in these patients after primary treatment.